Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
0.3190
Dollar change
0.0000
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.82 Insider Own5.91% Shs Outstand108.06M Perf Week70.28%
Market Cap34.47M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float25.38M Perf Month75.27%
Income- PEG- EPS next Q-0.19 Inst Own78.99% Short Float1.49% Perf Quarter98.53%
Sales- P/S- EPS this Y17.60% Inst Trans- Short Ratio0.03 Perf Half Y423.62%
Book/sh1.89 P/B0.17 EPS next Y57.10% ROA- Short Interest0.38M Perf Year397.21%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.05 - 0.39 Perf YTD87.43%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-17.95% Beta0.44
Dividend TTM0.00 (0.00%) Quick Ratio- Sales past 5Y- Gross Margin- 52W Low529.92% ATR (14)0.02
Dividend Ex-DateMar 15, 2024 Current Ratio- EPS Y/Y TTM22.09% Oper. Margin- RSI (14)82.81 Volatility14.40% 4.09%
Employees163 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price3.90
Option/ShortNo / No LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.00 Prev Close0.32
Sales Surprise- EPS Surprise33.33% Sales Q/Q- EarningsNov 13 AMC Avg Volume14.34M Price0.32
SMA2059.24% SMA5080.54% SMA200164.89% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Downgrade BofA Securities Buy → Underperform $5 → $3
Dec-22-23Downgrade Jefferies Buy → Hold $7 → $4
Mar-21-24 10:09AM
Mar-15-24 08:40AM
Feb-28-24 07:00AM
Feb-14-24 05:30AM
Feb-13-24 08:48AM
07:00AM Loading…
07:00AM
Dec-26-23 02:00AM
Dec-20-23 08:00AM
Dec-19-23 04:05PM
Dec-06-23 04:05PM
Dec-01-23 04:05PM
10:44AM
07:10AM
Nov-14-23 07:35PM
Nov-13-23 04:05PM
12:00PM Loading…
Nov-08-23 12:00PM
Oct-30-23 04:05PM
Oct-27-23 08:32AM
Oct-25-23 04:05PM
Oct-24-23 01:48PM
12:40PM
06:59AM
Aug-28-23 04:05PM
Aug-14-23 04:05PM
Aug-03-23 04:05PM
Jul-29-23 09:45AM
Jul-26-23 08:30AM
Jul-18-23 08:00AM
Jul-17-23 06:00AM
Jul-12-23 08:00AM
08:00AM Loading…
Jun-26-23 08:00AM
Jun-08-23 07:00AM
Jun-06-23 04:05PM
Jun-01-23 04:15PM
May-11-23 04:15PM
07:00AM
Apr-26-23 03:56PM
08:00AM
Apr-21-23 08:15AM
08:00AM
Mar-27-23 08:36AM
Mar-25-23 09:48AM
Dec-20-22 10:20AM
Dec-19-22 01:44PM
08:30AM
07:00AM
Dec-13-22 05:00PM
Nov-10-22 04:05PM
08:00AM
Nov-09-22 04:05PM
Nov-01-22 04:05PM
Oct-16-22 08:38AM
Oct-13-22 10:25AM
Oct-06-22 11:07AM
Sep-07-22 04:15PM
Aug-11-22 04:05PM
Aug-10-22 08:00AM
Jun-02-22 04:02PM
May-12-22 08:00AM
May-09-22 08:00AM
07:41AM
May-05-22 04:05PM
May-03-22 08:00AM
Apr-29-22 08:15AM
Apr-14-22 04:10PM
Apr-07-22 07:08PM
08:00AM
Mar-30-22 04:39PM
Mar-10-22 06:12PM
Feb-15-22 07:00AM
Feb-01-22 07:57AM
Jan-10-22 07:00AM
Dec-21-21 07:00AM
Dec-09-21 04:30PM
Dec-05-21 11:01AM
Nov-01-21 02:26PM
12:18PM
07:38AM
Oct-31-21 08:21PM
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLCDirectorFeb 15 '24Option Exercise2.5272,600182,95236,300Feb 20 05:25 PM
Stone Adam LeoInterim CEOFeb 15 '24Option Exercise2.5236,30091,47636,300Feb 20 05:23 PM
Poukalov KonstantinDirectorFeb 15 '24Option Exercise2.5236,30091,47636,300Feb 20 05:27 PM
GIANAKAKOS ANASTASIOSDirectorFeb 15 '24Option Exercise2.5236,30091,47672,848Feb 20 04:11 PM
Silbermann Susan MicheleDirectorFeb 15 '24Option Exercise2.5236,30091,47636,300Feb 20 04:10 PM